JP2016529235A5 - - Google Patents

Download PDF

Info

Publication number
JP2016529235A5
JP2016529235A5 JP2016526992A JP2016526992A JP2016529235A5 JP 2016529235 A5 JP2016529235 A5 JP 2016529235A5 JP 2016526992 A JP2016526992 A JP 2016526992A JP 2016526992 A JP2016526992 A JP 2016526992A JP 2016529235 A5 JP2016529235 A5 JP 2016529235A5
Authority
JP
Japan
Prior art keywords
optionally
amino
group
alkyl
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016526992A
Other languages
English (en)
Japanese (ja)
Other versions
JP6653253B2 (ja
JP2016529235A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/046203 external-priority patent/WO2015009545A1/en
Publication of JP2016529235A publication Critical patent/JP2016529235A/ja
Publication of JP2016529235A5 publication Critical patent/JP2016529235A5/ja
Application granted granted Critical
Publication of JP6653253B2 publication Critical patent/JP6653253B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016526992A 2013-07-16 2014-07-10 ホルミルペプチド受容体モジュレーターとしてのn−尿素置換アミノ酸の誘導体 Expired - Fee Related JP6653253B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361846787P 2013-07-16 2013-07-16
US61/846,787 2013-07-16
PCT/US2014/046203 WO2015009545A1 (en) 2013-07-16 2014-07-10 Derivatives of n-urea substituted amino acids as formyl peptide receptor modulators

Publications (3)

Publication Number Publication Date
JP2016529235A JP2016529235A (ja) 2016-09-23
JP2016529235A5 true JP2016529235A5 (enExample) 2017-08-17
JP6653253B2 JP6653253B2 (ja) 2020-02-26

Family

ID=51230227

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016526992A Expired - Fee Related JP6653253B2 (ja) 2013-07-16 2014-07-10 ホルミルペプチド受容体モジュレーターとしてのn−尿素置換アミノ酸の誘導体

Country Status (11)

Country Link
US (1) US9428549B2 (enExample)
EP (1) EP3022174B1 (enExample)
JP (1) JP6653253B2 (enExample)
KR (1) KR102313757B1 (enExample)
CN (1) CN105377814B (enExample)
AU (1) AU2014290618B2 (enExample)
CA (1) CA2917811C (enExample)
DK (1) DK3022174T3 (enExample)
ES (1) ES2708571T3 (enExample)
RU (1) RU2696581C2 (enExample)
WO (1) WO2015009545A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE040145T2 (hu) 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
AU2014226001B2 (en) 2013-03-06 2018-12-06 Allergan, Inc. Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases
BR112016011417A8 (pt) 2013-11-21 2020-05-05 Allergan Inc derivados de fenilcarbamatos como moduladores do receptor de formil peptídeo, composição farmacêutica, e seus usos
EP3305763B1 (en) 2013-11-28 2019-07-24 Kyorin Pharmaceutical Co., Ltd. Deuterated or isotopically labeled urea derivatives or pharmacologically acceptable salts thereof useful as fprl-1 agonists
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
KR20170005121A (ko) 2014-05-21 2017-01-11 알러간, 인코포레이티드 폼일 펩타이드 수용체 조절제로서의 이미다졸 유도체
AU2016266190A1 (en) 2015-05-27 2018-01-18 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
WO2016189877A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
TW201718473A (zh) * 2015-08-05 2017-06-01 歐樂根公司 作為甲醯肽受體1(fpr1)選擇性促效劑之苯基脲類似物
WO2019173182A1 (en) 2018-03-05 2019-09-12 Bristol-Myers Squibb Company Phenylpyrrolidinone formyl peptide 2 receptor agonists

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (fr) 1982-09-17 1984-03-23 Lyon I Universite Claude Edulcorants de synthese
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (ja) 1992-12-04 2003-03-17 富山化学工業株式会社 新規なフェニルアラニン誘導体またはその塩
US20030009022A1 (en) * 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
PT739903E (pt) * 1994-02-09 2002-05-31 Shionogi & Co Derivado carbamoilmetilureia
JP2968842B2 (ja) * 1994-02-09 1999-11-02 塩野義製薬株式会社 カルバモイルメチルウレア誘導体
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
US6548637B1 (en) * 1998-06-18 2003-04-15 Sepracor, Inc. Ligands for opioid receptors
JP2005536187A (ja) * 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト N−ホルミルペプチド受容体様1(fprl1)に関連する疾患の診断および治療
WO2005047899A2 (en) 2003-11-07 2005-05-26 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
JP5510945B2 (ja) * 2009-05-18 2014-06-04 アクテリオン ファーマシューティカルズ リミテッド Alx受容体及び/又はfprl2アゴニストとしての架橋スピロ[2.4]ヘプタン誘導体
AU2011336973A1 (en) * 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
HUE040145T2 (hu) 2011-10-26 2019-02-28 Allergan Inc N-karbamid szubsztituált aminosavak amid származékai mint formilpeptidszerû receptor 1 (FPRL1) receptormodulátorok
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8735622B2 (en) * 2011-11-30 2014-05-27 The Regents Of The University Of Colorado, A Body Corporate Histone demethylase inhibitors and methods for using the same
EP2964213B1 (en) * 2013-03-06 2020-11-04 Allergan, Inc. Use of agonists of formyl peptide receptor 2 for treating ocular inflammatory diseases
AU2014226001B2 (en) * 2013-03-06 2018-12-06 Allergan, Inc. Use of agonists of Formyl peptide receptor 2 for treating dermatological diseases

Similar Documents

Publication Publication Date Title
JP2017537940A5 (enExample)
RU2016104844A (ru) Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора
JP2016530310A5 (enExample)
JP2019514874A5 (enExample)
PH12020551616A1 (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
JP2016536364A5 (enExample)
JP2015537020A5 (enExample)
JP2014511892A5 (enExample)
JP2016503797A5 (enExample)
JP2017523225A5 (enExample)
JP2016515560A5 (enExample)
JP2014502979A5 (enExample)
RU2012125372A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2012513416A5 (enExample)
JP2017517538A5 (enExample)
JP2019501130A5 (enExample)
RU2017145930A (ru) МОДУЛЯТОРЫ ROR ГАММА (RORγ)
JP2015508092A5 (enExample)
JP2015535847A5 (enExample)
JP2016531126A5 (enExample)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
JP2019535723A5 (enExample)
JP2018048143A5 (enExample)
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
JP2020511547A5 (enExample)